Gelonghui, April 10 | Huisheng Biotech (300871.SZ) announced that it expects net profit of 19.5 million yuan to 25 million yuan in 2023, down 52.57% to 63% from the same period last year, after deducting non-net loss of 8.5 million yuan to 13 million yuan.
In the early stages, the company did not accrue individual credit impairment losses on accounts receivable from individual customers based on a comprehensive assessment of factors such as customer repayment conditions, financial changes, and development trends in the pig breeding industry. Due to new information recently obtained by the company, the customer showed signs of business risk and intended to apply to the court for restructuring and pre-restructuring. After thorough and thorough communication with the annual audit accounting firm, despite signs of recovery in the downstream pig breeding industry, the company added separate credit impairment losses based on the principle of prudence. This single credit impairment loss will cause the company's net profit in 2023 to drop by more than 50% compared to the same period last year. In 2023, the company's downstream pig breeding industry continued to lose money. Market demand was relatively sluggish, and sales revenue for chemical preparations declined.